<DOC>
	<DOCNO>NCT01558921</DOCNO>
	<brief_summary>Currently 3-year disease free survival patient locally advanced rectal cancer 50 % . Current standard treatment patient high risk fail locally and/or systemically include pre-operative long course radiotherapy ( 5 week ) combination chemotherapy ( call neoadjuvant chemoradiotherapy ) . The neoadjuvant chemoradiotherapy demonstrate improve local control , effect overall survival . Different study patient rectal cancer study effect adjuvant post operative chemotherapy result improve survival . This may due fact rectal cancer surgery ( TME ) associate high complication rate substantial proportion patient receive chemotherapy postoperatively . An alternative approach administer systemic therapy preoperative . To guarantee control rectum tumor short-course radiotherapy ( 5 day ) give , different study show local control tumor long time . During wait period patient good condition receive optimal dose chemotherapy . The investigator hypothesize propose protocol local tumour possible micrometastases effectively treat result increase survival . The investigator compare standard treatment neoadjuvant chemoradiation follow TME surgery optional adjuvant chemotherapy .</brief_summary>
	<brief_title>Rectal Cancer And Pre-operative Induction Therapy Followed Dedicated Operation . The RAPIDO Trial</brief_title>
	<detailed_description>Patients randomize experimental group ( arm B ) short course 5 x 5 Gy radiation scheme follow six cycle combination chemotherapy ( capecitabine/5FU oxaliplatin ) surgery control group ( arm A ) long course chemoradiotherapy follow surgery . In arm A adjuvant chemotherapy allow accord local protocol institution . In group rectal tumour remove TME surgery extensive surgery require tumour extent .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Primary tumour characteristic : 1 . Histological proof newly diagnose primary adenocarcinoma rectum 2 . Locally advanced tumour fulfil least one follow criterion pelvic MRI indicate high risk fail locally and/or systemically ( T4a , i.e . overgrowth adjacent organ structure like prostate , urinary bladder , uterus , sacrum , pelvic floor side wall ( accord TNM version 5 ) , cT4b , i.e . peritoneal involvement , extramural vascular invasion ( EMVI+ ) . N2 , i.e . four lymph node mesorectum show morphological sign MRI indicate metastatic disease . Positive MRF , i.e . tumor lymph node &lt; 1 mm mesorectal fascia . Enlarged lateral node , &gt; 1 cm ( lat LN+ ) 1 . Extensive growth cranial part sacrum ( S3 ) lumbosacral nerve root indicate surgery never possible even substantial tumour downsize see 2 . Presence metastatic disease recurrent rectal tumour 3 . Familial Adenomatosis Polyposis coli ( FAP ) , Hereditary NonPolyposis Colorectal Cancer ( HNPCC ) , active Crohn¡¦s disease active ulcerative Colitis 4 . Concomitant malignancy , except adequately treat basocellular carcinoma skin situ carcinoma cervix uterus . Subjects prior malignancy must diseasefree least 5 year 5 . Known DPD deficiency 6 . Any contraindication MRI ( e.g . patient pacemaker ) 7 . Medical psychiatric condition compromise patient 's ability give inform consent 8 . Concurrent uncontrolled medical condition 9 . Any investigational treatment rectal cancer within past month 10 . Pregnancy breast feed 11 . Patients know malabsorption syndrome lack physical integrity upper gastrointestinal tract 12 . Clinically significant ( i.e . active ) cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac dysrhythmia , e.g . atrial fibrillation , even control medication ) myocardial infarction within past 12 month 13 . Patients symptoms history peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>5x5</keyword>
	<keyword>capecitbine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>CAPOX</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>folinic acid</keyword>
	<keyword>fluorouracil</keyword>
</DOC>